

ESMO ADVANCED COURSE PROGRAMME

CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Barcelona, Spain
21-22 November 2025

CO-CHAIRS

Julien Edeline, France
Angela Lamarca, Spain

SPEAKERS

Marine Camus, France
Bas Groot Koerkamp, The Netherlands
Maeve Lowery, Ireland
Teresa Macarulla, Spain
David Malka, France
Victor Moreno, Spain
Anna Saborowski, Germany
Ana Vivancos, Spain

LEARNING OBJECTIVES

- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease

Friday, 21 November 2025

09:00-09:10 **Welcome and introduction**

10' Welcome and learning objectives
Julien Edeline, FR and Angela Lamarca, ES

09:10-10:35 **Session 1 – Understanding biliary tract tumours**

15' What are biliary tract tumours (primary site, epidemiology, and symptoms management)?
Teresa Macarulla, ES

15' The role of endoscopy
Marine Camus, FR

15' The role of pathology and molecular testing
Ana Vivancos, ES

20' The role of centers of expertise (role for surgery, role for systemic therapy)
Bas Groot Koerkamp, NL and Teresa Macarulla, ES

20' Discussion

10:35-11:05 *Coffee break*

11:05-12:10	Session 2 – Locoregional and surgical therapies
20'	Locoregional therapy: Is it ready for the clinic? Julien Edeline, FR
25'	Biliary drainage, surgery and transplant Bas Groot Koerkamp, NL
20'	Discussion
12:10-13:00	Session 3 – Adjuvant and neoadjuvant treatment
30'	Adjuvant and neoadjuvant treatment David Malka, FR
20'	Discussion
13:00-14:00	<i>Lunch</i>
14:00-15:00	Session 4 – The management of advanced disease: Chemotherapy and immunotherapy
20'	Chemotherapy - First line and second line: How is the field moving forward? Angela Lamarca, ES
20'	Immunotherapy: Rationale, current data, and upcoming studies Julien Edeline, FR
20'	Discussion
15:00-16:00	Session 5 – The management of advanced disease: Targeted therapies and new treatment options
20'	Targeted therapies FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development Maeve Lowery, IE
20'	Targeted therapies beyond FGFR, IDH and HER2: Current data and compounds in advanced (phase II and beyond) stage of development Anna Saborowski, DE
20'	Discussion
16:00-16:30	<i>Coffee break</i>
16:30-17:50	Session 6 – Bringing the latest science into patients care
10'	What can a phase I unit add to the management of BTC Victor Moreno, ES
15'	Ongoing clinical trials and status of drug approval Teresa Macarulla, ES
40'	Multidisciplinary tumour board Faculty
15'	Discussion
20:30	<i>Networking dinner</i>

Saturday, 22 November 2025

09:00-09:45 **MDT case discussion**
Faculty

09:45-12:30 **Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

10'	Introduction based on clinical cases presented by speakers
30'	Discussion
5'	Break

Workshop 1 Locoregional disease
Julien Edeline, FR and Bas Groot Koerkamp, NL

Workshop 2 Palliative chemotherapy (+/- immunotherapy)
Angela Lamarca, ES and David Malka, FR

Workshop 3 Molecular testing and targeted therapy
Maeve Lowery, IE and Anna Saborowski, DE

10:30-11:00 *Coffee break*

11:00-12:30 **Workshops continuation**

12:30-13:00 **Feedback on the workshops from each group**

13:00-13:15 **Synthesis and wrap-up**
Julien Edeline, FR and Angela Lamarca, ES

13:15-14:15 *Lunch*